Classification of teased nerve fibers for multicenter clinical trials

Journal of the Peripheral Nervous System

Volumn 4, Issue 3-4, 1999, Pages 233-244

  Kalichman, Michael W ^a   Chalk, Colin H ^b   Mizisin, Andrew P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Clinical trials; Neuropathology; Peripheral nerve

Indexed keywords

ARTICLE; DATA ANALYSIS; DEMYELINATION; HUMAN; HUMAN TISSUE; MYELIN SHEATH; NERVE BIOPSY; NERVE DEGENERATION; NERVE FIBER; NEUROPATHOLOGY; OBSERVER VARIATION; PERIPHERAL NERVE; PRIORITY JOURNAL; REMYELINIZATION; SURAL NERVE;

BIOPSY; FALSE POSITIVE REACTIONS; HUMANS; MULTICENTER STUDIES; MYELIN SHEATH; NERVE FIBERS; SURAL NERVE; WALLERIAN DEGENERATION;

EID: 0033382678     PISSN: 10859489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dyck PJ, Giannini C, Lais A: Pathologic alterations of nerves. In: Peripheral Neuropathy (Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds). 3rd ed., Philadelphia: WB Saunders Co., 1993, 528-562.
2. Ghabriel MN, Allt G: The role of Schmidt-Lanterman incisures in Wallerian degeneration. I. A quantitative teased fibre study. Acta Neuropathol. (Berl.) 1979; 48(2):93-93.
3. Richardson PM, Thomas PK: Percussive injury to peripheral nerve in rats. J. Neurosurg. 1979; 51(2):178-187.
4. Dyck PJ, O'Brien PC, Ohnishi A: Lead neuropathy: 2. Random distribution of segmental demyelination among "old internodes" of myelinated fibers. J. Neuropathol. Exp. Neurol. 1977; 36(3):570-575.
5. Powell HC, Koch T, Garrett R, Lampert PW: Schwann cell abnormalities in 2,5-hexanedione neuropathy. J. Neurocytol. 1978; 7(4):517-528.
6. Spencer PS, Schaumburg HH: Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration. J. Neuropathol. Exp. Neurol. 1977; 36(2):276-299.
7. Midroni G, Bilbao JM: Biopsy Diagnosis of Peripheral Neuropathy. Boston: Butterworth-Heinemann, 1995.
8. Sima AA, Bril V, Nathaniel V, McEwen TA, Brown MB, Lattimer SA, Greene DA: Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N. Engl. J. Med. 1988; 319(9):548-555.
9. Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B: Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. J. Diabetes Complications 1993; 7(3):157-169.
10. Johnson PC, Doll SC, Cromey DW: Pathogenesis of diabetic neuropathy. Ann. Neurol. 1986; 19:450-457.
11. Coons SW, Johnson PC, Scheithauer, BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and inter-observer concordance in the classification and grading of primary gliomas. Cancer 1997; 79:1381-1393.
12. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW: Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J. Neuropathol. Exp. Neurol. 1996; 55(1):97-105.
13. Dyck PJ, Johnson WJ, Lambert EH, O'Brien PC: Segmental demyelination secondary to axonal degeneration in uremic neuropathy. Mayo Clin. Proc. 1971; 46:400-431.
14. Dyck PJ: Pathologic alterations of the peripheral nervous system of man. In: Peripheral Neuropathy (Dyck PJ, Thomas PK, Lambert EH, eds). 1st ed., Philadelphia: WB Saunders Co., 1975, 528-562.
15. Waxman SG: Prerequisites for conduction in demyelinated fibers. Neurology 1978; 28(9 Pt 2):27-33.
16. Rushton WAH: A theory of the effects of fibre size in medullated nerve. J. Physiol. (Lond.) 1951; 115:101-122.
17. Waxman SG: Determinants of conduction velocity in myelinated nerve fibers. Muscle and Nerve 1980; 3: 141-150.
18. Griffin JW, Li CY, Macko C, Ho TW, Hsieh S-T, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK: Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J. Neurocytol. 1996; 25(1):33-51.
19. Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA: Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J. Clin. Invest. 1988; 81(2):349-364.
20. Thomas PK, Beamish NG, Small JR, et al: Paranodal structure in diabetic sensory polyneuropathy. Acta Neuropathol. (Berl.) 1996; 92(6):614-620.
21. Giannini C, Dyck PJ: Axoglial dysjunction: a critical appraisal of definition, techniques, and previous results. Microsc. Res. Tech. 1996; 34(5):436-444.
22. Sima AAF: Pathological alterations in the diabetic neuropathies of humans. J. Neuropathol. Exp. Neurol. 1997; 56:458.
23. Sima AA, Prashar A, Zhang WX, Chakrabarti S, Greene DA: Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat. J. Clin. Invest. 1990; 85(5): 1410-1420.
24. O'Neill JH, Jacobs JM, Gilliatt RW, Baba M: Changes in the compact myelin of single internodes during axonal atrophy. Acta Neuropathol. (Berl.) 1984; 63:313-318.
25. Sima AA, Dunlap JA, Davidson EP, et al: Supplemental myo-inositol prevents L-fucose-induced diabetic neuropathy. Diabetes 1997; 46(2):301-306.
26. Peripheral Nerve Society: Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society. Ann. Neurol. 1995; 38(3):478-482.
27. Williams PL, Hall SM: Prolonged in vivo observations of normal peripheral nerve fibres and their acute reactions to crush and deliberate trauma. J. Anat. 1971; 108(3):397-408.